Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study
| Autor: | Claudy Mullon, Daniel W. Coyne, Linda H. Ficociello, Vidhya Parameswaran, Nicolaos V. Athienites, Kamyar Kalantar-Zadeh, Robert J. Kossmann |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
Nephrology Sucrose medicine.medical_treatment lcsh:RC870-923 Ferric Compounds Gastroenterology Cohort Studies chemistry.chemical_compound Phosphate binder Medicine Hypoalbuminemia Wasting biology Drug Substitution Phosphorus Middle Aged Drug Combinations Parathyroid Hormone Creatinine Hemodialysis Female Dietary Proteins medicine.symptom Research Article medicine.medical_specialty medicine.drug_class Serum albumin Phosphates Renal Dialysis Internal medicine Humans Renal Insufficiency Chronic Sucroferric oxyhydroxide Serum Albumin Retrospective Studies business.industry Albumin Phosphate medicine.disease lcsh:Diseases of the genitourinary system. Urology chemistry Phosphorous biology.protein business |
| Zdroj: | BMC Nephrology, Vol 20, Iss 1, Pp 1-8 (2019) BMC Nephrology |
| ISSN: | 1471-2369 |
| DOI: | 10.1186/s12882-019-1582-9 |
| Popis: | Background Elevated serum phosphorus concentrations are common among maintenance hemodialysis patients. Protein is a major source of dietary phosphate, but restriction of protein intake can result in hypoalbuminemia and protein-energy wasting. We hypothesized that sucroferric oxyhydroxide (SO), a potent phosphate binder with a low pill burden, may reduce serum phosphorus levels in hemodialysis patients with hypoalbuminemia without adversely impacting albumin levels or dietary intake of protein. Methods We retrospectively examined de-identified data from 79 adult, in-center hemodialysis patients with baseline hypoalbuminemia (≤ 3.5 g/dL) switched to SO as part of routine clinical care for at least 1 year. Temporal changes (3-month intervals from baseline through Q4) in phosphate binder pill burden, serum phosphorous levels, nutritional markers, and equilibrated Kt/V were analyzed. Data from a matched reference group of non-hypoalbuminemic patients (N = 79) switched to SO were also examined. Results SO therapy was associated with a mean reduction of 45.7 and 45.1% in daily phosphate binder pill burden, and a mean reduction of 0.4 mg/dL and 0.51 mg/dL in serum phosphorus levels for the hypoalbuminemic and non-hypoalbuminemic patients, respectively. Hypoalbuminemic patients demonstrated significant increases in mean serum albumin levels from 3.50 mg/dL at baseline to 3.69, 3.74, 3.70, and 3.69 mg/dL during Q1 through Q4, respectively (P Conclusions Both hypoalbuminemic and non-hypoalbuminemic patients switching to SO exhibited significant reductions in serum phosphorus concentrations and daily phosphate binder pill burden. Among hypoalbuminemic patients, the initiation of SO therapy was also associated with increases in serum albumin, suggesting therapy may have allowed patients to increase their dietary intake of protein. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink